Molecular Pathology Laboratory Network

Nearly 139,000 Americans are affected by leukemia or lymphoma, and every 10 minutes someone is expected to die from one of these two forms of blood cancers.  To bring attention to these life-threatening diseases, September is recognized as Leukemia and Lymphoma Awareness Month.

MPLN offers a comprehensive test menu for the prognosis and diagnosis of leukemia and lymphoma as well as targeted assays to help physicians select appropriate treatment options and monitor therapy effectiveness in individual patients. 

Through StrataFLEX^TM, an innovative health management strategy, clinicians are provided a step-by-step approach to patient-specific testing using evidence-based medicine. This in-house multidisciplinary approach maximizes information from a single sample, while minimizing cost for the patient. 

"A leukemia/lymphoma patient can present a number of diagnostic and  prognostic challenges for the physician," said Dr. Nicholas T. Potter, director of molecular diagnostics and chief scientific officer for MPLN. "In this regard, our ability to offer a number of  complementary technologies such as flow cytometry, cytogenetics, fluorescence in situ hybridization, gene sequencing, quantitative PCR and immunohistochemistry, allows us to maximize the number of relevant tests that can be performed on the specimen while minimizing the complexity of the testing process." 

MPLN enhances the overall health management process by making diagnostic decisions easier for clients through the delivery of reliable, comprehensive and clinically relevant results in a timely fashion.

To monitor treatment success and the detection of minimal residual disease (MRD), MPLN also offers several sensitive quantitative PCR-based tests for the detection of the PML-RARA gene fusions (long and short forms) in acute promyelocytic leukemia (APL/AML-M3) and BCR-ABL gene fusions (major and minor) in chronic myeloid leukemia and acute lymphoblastic leukemia. 

For more information our tests for the prognosis, diagnosis and monitoring of leukemia and lymphoma, contact a client service specialist at 800.932.2943.